Bevacizumab — Dosing in CKD & Dialysis
Bevacizumab (Antineoplastic): renal dosing adjustments, dialyzability (Negligible (dialyser extraction 0% and hemodialysis clearance 0 mL/min in one HD patient; Garnier-Viougeat 2007, PMID 17093010)), and renal-relevant safety risk for CKD and dialysis patients. Educational reference for nephrology
Reviewed by Matt · November 16, 2026